Cargando…

IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma

Indoleamine 2,3-dioxygenase (IDO1) plays an important role in tumor immune evasion. In this study, we investigated the changes of tumor IDO1 expression and CD8+ tumor-infiltrating lymphocytes (TILs) status in tumor microenvironment (TME) after neoadjuvant chemoradiotherapy (NCRT) or neoadjuvant chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiao, Ruidi, Zheng, Xiaoli, Sun, Yanan, Feng, Zhuo, Song, Shuai, Ge, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358399/ https://www.ncbi.nlm.nih.gov/pubmed/32733806 http://dx.doi.org/10.3389/fonc.2020.01099

Ejemplares similares

Upregulation of IBSP Expression Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma
por: Wang, Mingyue, et al.
Publicado: (2019)

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

Increased Expression of SHMT2 Is Associated With Poor Prognosis and Advanced Pathological Grade in Oral Squamous Cell Carcinoma
por: Wu, Zhi-Zhong, et al.
Publicado: (2020)

Prediction of pathological response grading for esophageal squamous carcinoma after neoadjuvant chemoradiotherapy based on MRI imaging using PDX
por: Shi, Jingzhen, et al.
Publicado: (2023)

Increases prognostic value of clinical-pathological nomogram in patients with esophageal squamous cell carcinoma
por: Hu, Jing Feng, et al.
Publicado: (2023)

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Predictive Value of Endoscopic Observations and Biopsy After Neoadjuvant Chemoradiotherapy in Assessing the Pathologic Complete Response of Patients With Esophageal Squamous Cell Carcinoma
por: Taghizadeh Kermani, Ali, et al.
Publicado: (2022)

Nomogram constructed by immunological and inflammatory indicators for predicting prognosis of patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy plus surgery
por: Luo, Yun, et al.
Publicado: (2022)

Targeting valosin‐containing protein enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma
por: Luo, Hui, et al.
Publicado: (2019)

Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy
por: Yang, Yang, et al.
Publicado: (2020)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy
por: He, Wenwu, et al.
Publicado: (2021)

FLVCR1 Predicts Poor Prognosis and Promotes Malignant Phenotype in Esophageal Squamous Cell Carcinoma via Upregulating CSE1L
por: Zhou, Suna, et al.
Publicado: (2021)

Upregulation of PEDF Predicts a Poor Prognosis and Promotes Esophageal Squamous Cell Carcinoma Progression by Modulating the MAPK/ERK Signaling Pathway
por: Chen, Zui, et al.
Publicado: (2021)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

Brain Metastases from Esophageal Squamous Cell Carcinoma: Clinical Characteristics and Prognosis
por: Xiao, Linlin, et al.
Publicado: (2021)

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
por: Jiang, Dongxian, et al.
Publicado: (2023)

Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway
por: Wu, Xiangyu, et al.
Publicado: (2021)

Optimal Range of Lymphadenectomy in Pathological Stage T1 and T2 Esophageal Squamous Cell Carcinoma
por: Wu, Hansheng, et al.
Publicado: (2021)

Corrigendum: Brain Metastases from Esophageal Squamous Cell Carcinoma: Clinical Characteristics and Prognosis
por: Xiao, Linlin, et al.
Publicado: (2022)

Clinicopathological characteristics and postoperative prognosis of patients with nuclear pedigree of esophageal squamous cell carcinoma
por: Wei, Meng Xia, et al.
Publicado: (2023)

Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
por: Ji, Wenbing, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Mefloquine Inhibits Esophageal Squamous Cell Carcinoma Tumor Growth by Inducing Mitochondrial Autophagy
por: Xie, Yifei, et al.
Publicado: (2020)

The angiogenic genes predict prognosis and immune characteristics in esophageal squamous cell carcinoma: Evidence from multi-omics and experimental verification
por: Wang, Shuaiyuan, et al.
Publicado: (2022)

Serum Metabolomic Profiling Reveals Biomarkers for Early Detection and Prognosis of Esophageal Squamous Cell Carcinoma
por: Wang, Pan Pan, et al.
Publicado: (2022)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Increased copy number of mitochondrial DNA predicts poor prognosis of esophageal squamous cell carcinoma
por: Li, Heng, et al.
Publicado: (2018)

Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
por: Li, Yue, et al.
Publicado: (2021)

Genomic Variations in Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma
por: Yasar, Hatime A
Publicado: (2023)

Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy
por: La Mendola, Roberta, et al.
Publicado: (2020)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial
por: Wang, Ying-Jian, et al.
Publicado: (2022)

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
por: Huang, Runkai, et al.
Publicado: (2022)

Overexpression of Mena is associated with tumor progression and poor prognosis in oral squamous cell carcinoma via EMT
por: Na, Sijia, et al.
Publicado: (2022)

Lymphopenia Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma
por: Feng, Ji-Feng, et al.
Publicado: (2014)

EP300 as an oncogene correlates with poor prognosis in esophageal squamous carcinoma
por: Bi, Yanghui, et al.
Publicado: (2019)

DEK overexpression is predictive of poor prognosis in esophageal squamous cell carcinoma
por: Yi, Huochun, et al.
Publicado: (2019)

Transcriptional factor regulation network and competitive endogenous RNA (ceRNA) network determining response of esophageal squamous cell carcinomas to neoadjuvant chemoradiotherapy
por: Shao, Mingrui, et al.
Publicado: (2019)

Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis
por: Ma, Zeliang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h1fh1vnt6emctjfs29o7uk5bh2